Characteristics | HCV G1 (n=34) | HCV G1+NAS (n=32) |
Age (years) | 42.5 (21−64) | 43.5 (23−67) |
Female gender | 18 (52.9%) | 19 (59.4%) |
Body mass index (kg/m2) | 25.9 (19.8−31.2) | 26.8 (20.2−35.7) |
Glucose (mg/dl) | 95.4 (76−114) | 97.1 (82−117) |
Insulin (μU/l) | 8.1 (3.6−18.9) | 12.6 (3.9−23.1)* |
HOMA-IR | 0.95 (0.5−2.9) | 1.80 (0.5−3.4)* |
Triglycerides (mg/dl) | 80.0 (28−183) | 87.5 (53−208) |
HDL-cholesterol (mg/dl) | 47.0 (35−75) | 46.5 (36−72) |
ALT (IU/l) | 68.5 (21−271) | 76.5 (32−276) |
AST (IU/l) | 43.5 (15−125) | 49.0 (32−144) |
γGT (IU/l) | 25.0 (17−130) | 60.5 (15−221)* |
Viral load (%) | ||
≤8.5×105 IU/ml | 15 (44.1%) | 14 (43.7%) |
>8.5×105 IU/ml | 19 (55.9%) | 18 (56.3%) |
Steatosis (%) | ||
Grade 0 | 34 (100%) | |
Grade 1 | 19 (59.4%) | |
Grade 2 | 9 (28.1%) | |
Grade 3 | 4 (12.5%) | |
Fibrosis (%) | ||
Stage 0 | 9 (26.5%) | 8 (25.0%) |
Stage 1 | 12 (35.3%) | 9 (28.1%) |
Stage 2 | 9 (26.5%) | 10 (31.3%) |
Stage 3 | 4 (11.7%) | 5 (15.6%) |
Stage 4 | ||
Necroinflammation (%) | ||
Grade 0 | 3 (8.8%) | 3 (9.4%) |
Grade 1 | 11 (32.4%) | 11 (34.4%) |
Grade 2 | 15 (44.1%) | 12 (37.5%) |
Grade 3 | 5 (14.7%) | 6 (18.8%) |
Data are shown as median (range) or n (%).
* p<0.05 vs HCV group.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, gamma-glutamyltransferase; HCV G1, hepatitis C virus genotype 1; HCV G1+NAS, hepatitis C virus genotype 1 with non-alcoholic steatosis; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance.